Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Multiple Sclerosis Performance Test: Validation of Self-Administered Neuroperformance Modules.

Rao SM, Galioto R, Sokolowski M, McGinley M, Freiburger J, Weber M, Dey T, Mourany L, Schindler D, Reece C, Miller DM, Bethoux F, Bermel RA, Williams JR, Levitt N, Phillips GA, Rhodes JK, Alberts J, Rudick RA.

Eur J Neurol. 2020 Feb 3. doi: 10.1111/ene.14162. [Epub ahead of print]

PMID:
32009276
2.

Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice.

Baldassari LE, Nakamura K, Moss BP, Macaron G, Li H, Weber M, Jones SE, Rao SM, Miller D, Conway DS, Bermel RA, Cohen JA, Ontaneda D, McGinley MP.

Mult Scler Relat Disord. 2019 Nov 14;38:101525. doi: 10.1016/j.msard.2019.101525. [Epub ahead of print]

PMID:
31759186
3.

Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation.

Baldassari LE, Planchon SM, Bermel RA, Nakamura K, Fisher E, Feng J, Sakaie KE, Ontaneda D, Cohen JA.

Mult Scler J Exp Transl Clin. 2019 Nov 5;5(4):2055217319887198. doi: 10.1177/2055217319887198. eCollection 2019 Oct-Dec.

4.

Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.

Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM.

J Neurol Sci. 2019 Dec 15;407:116498. doi: 10.1016/j.jns.2019.116498. Epub 2019 Oct 15.

5.

Multiple Sclerosis Performance Test: Technical Development and Usability.

Rhodes JK, Schindler D, Rao SM, Venegas F, Bruzik ET, Gabel W, Williams JR, Phillips GA, Mullen CC, Freiburger JL, Mourany L, Reece C, Miller DM, Bethoux F, Bermel RA, Krupp LB, Mowry EM, Alberts J, Rudick RA.

Adv Ther. 2019 Jul;36(7):1741-1755. doi: 10.1007/s12325-019-00958-x. Epub 2019 May 3.

6.

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators.

N Engl J Med. 2018 Aug 30;379(9):846-855. doi: 10.1056/NEJMoa1803583.

7.

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers.

Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM.

Neurol Clin Pract. 2018 Aug;8(4):292-301. doi: 10.1212/CPJ.0000000000000487.

8.

Outer Retinal Assessment Using Spectral-Domain Optical Coherence Tomography in Patients With Alzheimer's and Parkinson's Disease.

Uchida A, Pillai JA, Bermel R, Bonner-Jackson A, Rae-Grant A, Fernandez H, Bena J, Jones SE, Leverenz JB, Srivastava SK, Ehlers JP.

Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2768-2777. doi: 10.1167/iovs.17-23240.

9.

A brief history of NEDA.

Giovannoni G, Bermel R, Phillips T, Rudick R.

Mult Scler Relat Disord. 2018 Feb;20:228-230. doi: 10.1016/j.msard.2017.07.011. Epub 2017 Jul 13. No abstract available.

PMID:
29579628
10.

The role of the thalamus and hippocampus in episodic memory performance in patients with multiple sclerosis.

Koenig KA, Rao SM, Lowe MJ, Lin J, Sakaie KE, Stone L, Bermel RA, Trapp BD, Phillips MD.

Mult Scler. 2019 Apr;25(4):574-584. doi: 10.1177/1352458518760716. Epub 2018 Mar 7.

PMID:
29512427
11.

Triaging Patients with Multiple Sclerosis in the Emergency Department: Room for Improvement.

Abboud H, Mente K, Seay M, Kim J, Ali A, Bermel R, Willis MA.

Int J MS Care. 2017 Nov-Dec;19(6):290-296. doi: 10.7224/1537-2073.2016-069.

12.

Unravelling neurodegeneration in multiple sclerosis.

Bermel RA.

Lancet Neurol. 2017 Oct;16(10):764-766. doi: 10.1016/S1474-4422(17)30302-2. Epub 2017 Sep 12. No abstract available.

PMID:
28920874
13.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.

Hersh CM, Love TE, Bandyopadhyay A, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D.

Mult Scler J Exp Transl Clin. 2017 Aug 24;3(3):2055217317715485. doi: 10.1177/2055217317715485. eCollection 2017 Jul-Sep.

14.

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct;24(11):1469-1484. doi: 10.1177/1352458517723718. Epub 2017 Aug 11. Review.

15.

Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M, Morrison S, Reese Koc J, Gerson SL, Lazarus HM.

Mult Scler. 2018 Apr;24(4):501-511. doi: 10.1177/1352458517703802. Epub 2017 Apr 6.

16.

Processing speed test: Validation of a self-administered, iPad®-based tool for screening cognitive dysfunction in a clinic setting.

Rao SM, Losinski G, Mourany L, Schindler D, Mamone B, Reece C, Kemeny D, Narayanan S, Miller DM, Bethoux F, Bermel RA, Rudick R, Alberts J.

Mult Scler. 2017 Dec;23(14):1929-1937. doi: 10.1177/1352458516688955. Epub 2017 Jan 12.

PMID:
28080262
17.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.

Hersh CM, Love TE, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D.

Mult Scler Relat Disord. 2016 Nov;10:44-52. doi: 10.1016/j.msard.2016.08.002. Epub 2016 Aug 8.

PMID:
27919497
18.

Heterogeneous depression trajectories in multiple sclerosis patients.

Gunzler DD, Morris N, Perzynski A, Ontaneda D, Briggs F, Miller D, Bermel RA.

Mult Scler Relat Disord. 2016 Sep;9:163-9. doi: 10.1016/j.msard.2016.08.004. Epub 2016 Aug 5.

19.

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R, Ashokkumar A, Bermel R, Ecklund D, Koepp M, Long J, Natarajan S, Ramachandran S, Skaramagas T, Thornell B, Yankey J, Agius M, Bashir K, Cohen B, Coyle P, Delgado S, Dewitt D, Flores A, Giesser B, Goldman M, Jubelt B, Lava N, Lynch S, Miravalle A, Moses H, Ontaneda D, Perumal J, Racke M, Repovic P, Riley C, Severson C, Shinnar S, Suski V, Weinstock-Gutman B, Yadav V, Zabeti A.

Contemp Clin Trials. 2016 Sep;50:166-77. doi: 10.1016/j.cct.2016.08.009. Epub 2016 Aug 10.

20.

Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial.

White JT, Newsome SD, Kieseier BC, Bermel RA, Cui Y, Seddighzadeh A, Hung S, Crossman M, Subramanyam M.

Ther Adv Neurol Disord. 2016 Jul;9(4):239-49. doi: 10.1177/1756285616633967. Epub 2016 Mar 10.

21.

Relapses in multiple sclerosis: Relationship to disability.

Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, Miller AE, Pelletier D, Racke MK, Trapp BD, Vartanian T, Waubant E.

Mult Scler Relat Disord. 2016 Mar;6:10-20. doi: 10.1016/j.msard.2015.09.002. Epub 2015 Sep 8. Review.

PMID:
27063617
22.

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.

Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P; IMSVISUAL consortium.

Lancet Neurol. 2016 May;15(6):574-84. doi: 10.1016/S1474-4422(16)00068-5. Epub 2016 Mar 18.

PMID:
27011339
23.

Retinal Nerve Fiber Layer Thinning in Alzheimer's Disease: A Case-Control Study in Comparison to Normal Aging, Parkinson's Disease, and Non-Alzheimer's Dementia.

Pillai JA, Bermel R, Bonner-Jackson A, Rae-Grant A, Fernandez H, Bena J, Jones SE, Ehlers JP, Leverenz JB.

Am J Alzheimers Dis Other Demen. 2016 Aug;31(5):430-6. doi: 10.1177/1533317515628053. Epub 2016 Feb 16.

PMID:
26888864
24.

Optical Coherence Tomography for the Detection of Remote Optic Neuritis in Multiple Sclerosis.

Xu LT, Bermel RA, Nowacki AS, Kaiser PK.

J Neuroimaging. 2016 May;26(3):283-8. doi: 10.1111/jon.12326. Epub 2016 Jan 15.

PMID:
26773711
25.

Erratum to: Disentangling Multiple Sclerosis and depression: an adjusted depression screening score for patient-centered care.

Gunzler DD, Perzynski A, Morris N, Bermel R, Lewis S, Miller D.

J Behav Med. 2016 Feb;39(1):178. doi: 10.1007/s10865-015-9685-7. No abstract available.

26.

The relationship between cognitive function and high-resolution diffusion tensor MRI of the cingulum bundle in multiple sclerosis.

Koenig KA, Sakaie KE, Lowe MJ, Lin J, Stone L, Bermel RA, Beall EB, Rao SM, Trapp BD, Phillips MD.

Mult Scler. 2015 Dec;21(14):1794-801. doi: 10.1177/1352458515576983. Epub 2015 Jun 23.

27.

Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors.

Bermel RA, Hashmonay R, Meng X, Randhawa S, von Rosenstiel P, Sfikas N, Kantor D.

Mult Scler Relat Disord. 2015 May;4(3):273-80. doi: 10.1016/j.msard.2015.04.002. Epub 2015 Apr 13.

28.

Using MRI to make informed clinical decisions in multiple sclerosis care.

Bermel RA, Naismith RT.

Curr Opin Neurol. 2015 Jun;28(3):244-9. doi: 10.1097/WCO.0000000000000204. Review.

PMID:
25887772
29.

Experience with fingolimod in clinical practice.

Hersh CM, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA, Ontaneda D.

Int J Neurosci. 2015;125(9):678-85. doi: 10.3109/00207454.2014.969839. Epub 2014 Oct 29.

30.

Anatomic connectivity assessed using pathway radial diffusivity is related to functional connectivity in monosynaptic pathways.

Lowe MJ, Koenig KA, Beall EB, Sakaie KA, Stone L, Bermel R, Phillips MD.

Brain Connect. 2014 Sep;4(7):558-65. doi: 10.1089/brain.2014.0265.

PMID:
25117651
31.

Outcome measures in multiple sclerosis.

Bermel R, Waldman A, Mowry EM.

Mult Scler Int. 2014;2014:439375. doi: 10.1155/2014/439375. Epub 2014 May 5. No abstract available.

32.

Disentangling Multiple Sclerosis and depression: an adjusted depression screening score for patient-centered care.

Gunzler DD, Perzynski A, Morris N, Bermel R, Lewis S, Miller D.

J Behav Med. 2015 Apr;38(2):237-50. doi: 10.1007/s10865-014-9574-5. Epub 2014 Jun 1. Erratum in: J Behav Med. 2016 Feb;39(1):178.

33.

Retrograde trans-synaptic degeneration in MS: a missing link?

Bermel RA, Villoslada P.

Neurology. 2014 Jun 17;82(24):2152-3. doi: 10.1212/WNL.0000000000000532. Epub 2014 May 16. No abstract available.

PMID:
24838792
34.

Simple MRI metrics contribute to optimal care of the patient with multiple sclerosis.

Simon JH, Bermel RA, Rudick RA.

AJNR Am J Neuroradiol. 2014 May;35(5):831-2. doi: 10.3174/ajnr.A3937. Epub 2014 Apr 3. No abstract available.

35.

Hippocampal volume is related to cognitive decline and fornicial diffusion measures in multiple sclerosis.

Koenig KA, Sakaie KE, Lowe MJ, Lin J, Stone L, Bermel RA, Beall EB, Rao SM, Trapp BD, Phillips MD.

Magn Reson Imaging. 2014 May;32(4):354-8. doi: 10.1016/j.mri.2013.12.012. Epub 2013 Dec 30.

36.

Optic neuritis and the evaluation of visual impairment in multiple sclerosis.

Bermel RA, Balcer LJ.

Continuum (Minneap Minn). 2013 Aug;19(4 Multiple Sclerosis):1074-86. doi: 10.1212/01.CON.0000433282.00221.7e. Review.

PMID:
23917102
37.

Sex differences in resting-state functional connectivity in multiple sclerosis.

Koenig KA, Lowe MJ, Lin J, Sakaie KE, Stone L, Bermel RA, Beall EB, Rao SM, Trapp BD, Phillips MD.

AJNR Am J Neuroradiol. 2013 Dec;34(12):2304-11. doi: 10.3174/ajnr.A3630. Epub 2013 Jun 27.

38.
39.

Sensorimotor cortex gamma-aminobutyric acid concentration correlates with impaired performance in patients with MS.

Bhattacharyya PK, Phillips MD, Stone LA, Bermel RA, Lowe MJ.

AJNR Am J Neuroradiol. 2013 Sep;34(9):1733-9. doi: 10.3174/ajnr.A3483. Epub 2013 Mar 14.

40.

Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

Bermel RA, You X, Foulds P, Hyde R, Simon JH, Fisher E, Rudick RA.

Ann Neurol. 2013 Jan;73(1):95-103. doi: 10.1002/ana.23758.

PMID:
23378325
41.

High spatial and angular resolution diffusion-weighted imaging reveals forniceal damage related to memory impairment.

Koenig KA, Sakaie KE, Lowe MJ, Lin J, Stone L, Bermel RA, Beall EB, Rao SM, Trapp BD, Phillips MD.

Magn Reson Imaging. 2013 Jun;31(5):695-9. doi: 10.1016/j.mri.2012.10.030. Epub 2013 Jan 5.

42.

Neurodegeneration and inflammation in MS: the eye teaches us about the storm.

Bermel RA, Inglese M.

Neurology. 2013 Jan 1;80(1):19-20. doi: 10.1212/WNL.0b013e31827b1b6c. No abstract available.

PMID:
23267029
43.

Early tolerability and safety of fingolimod in clinical practice.

Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA.

J Neurol Sci. 2012 Dec 15;323(1-2):167-72. doi: 10.1016/j.jns.2012.09.009. Epub 2012 Oct 3.

44.

Fulminant cerebral demyelination in neuromyelitis optica.

Newey CR, Bermel RA.

Neurology. 2011 Jul 12;77(2):193. doi: 10.1212/WNL.0b013e3182242d6e. No abstract available.

PMID:
21747076
45.

Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options.

Bermel RA, Cohen JA.

Lancet Neurol. 2011 Jan;10(1):4-5. doi: 10.1016/S1474-4422(10)70282-9. No abstract available.

PMID:
21163434
46.

MRI in multiple sclerosis.

Bermel RA, Fox RJ.

Continuum (Minneap Minn). 2010 Oct;16(5 Multiple Sclerosis):37-57. doi: 10.1212/01.CON.0000389933.77036.14.

PMID:
22810597
47.

Diagnosing multiple sclerosis at a later age: more than just progressive myelopathy.

Bermel RA, Rae-Grant AD, Fox RJ.

Mult Scler. 2010 Nov;16(11):1335-40. doi: 10.1177/1352458510377334. Epub 2010 Jul 29.

PMID:
20670982
48.

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.

Bermel RA, Weinstock-Guttman B, Bourdette D, Foulds P, You X, Rudick RA.

Mult Scler. 2010 May;16(5):588-96. doi: 10.1177/1352458509360549. Epub 2010 Feb 18.

PMID:
20167591
49.

Picturing injury and recovery with diffusion tensor imaging: the eyes have it.

Bermel RA, Fox RJ.

Neurology. 2009 Feb 17;72(7):584-5. doi: 10.1212/01.wnl.0000336559.52816.16. Epub 2008 Dec 10. No abstract available.

PMID:
19073946
50.

The use of MR imaging as an outcome measure in multiple sclerosis clinical trials.

Bermel RA, Fisher E, Cohen JA.

Neuroimaging Clin N Am. 2008 Nov;18(4):687-701, xi. doi: 10.1016/j.nic.2008.06.008. Review.

PMID:
19068409

Supplemental Content

Loading ...
Support Center